Pioneer Ecosystems phone calls Day 1- how bad was it??

[anonymous]

Watch out everyone ... there is a hunt to put targets on people’s backs and if you don’t believe it look at Lytics. They are looking to lay-off for any reason. The RSD is a talking head and doesn’t stand up for anything. She should have never been hired over here. Her extracurricular activities with a married marketer should be grounds for termination.

Everyone knew about this in BioOnc and hone office. Pretty obvious. She is a snake.

 

[anonymous]

Wow, it finally hit the fan. I used to work for the consulting company that sold this product. I was on this project for almost a year. I left before it was completed because my sister threatened to disown me when her drug rep husband lost his job. I must say that everyone on my team hated drug companies, especially their sale people. I am the oldest guy on the team. They are all millennials and just despised drug firms. Our boss is a total douche bag. We knew we couldn't sell realignment/restructuring products for another year. Most companies have gotten smarter and were not buying it. They would do it internally. So we spent weeks coming up with this flex model or what they finally called ecosystem. It is an old product with a spin. We cherry picked our market consultants to package the data. It was a freaking joke. Sorry you guys are duped. Glad I am out of that business. Karma can be a bitch.

 

[anonymous]

Not worried at all. Collecting two years of salary in the same year. Signing bonus, 16% raise in base, smaller geography, so an 8 hour day will be easy instead of driving ungodly hours, incentive compensation plan uncapped, leadership that is sound, better benefits that cost a quarter of what your people will pay, and most importantly, a strong pipeline and job security- none of which Genentech is offering to external candidates or even the poor internal souls left to bail the water out of the hole in the boat. The North Koreans have a better work environment than the ecosystems. Your people are skeptical, scared and all are looking elsewhere. A few in the ecosystem have already accepted offers elsewhere. Watch the movement. Genentech will be bought. No longer considered a player in the industry. Biosimilars will clean your clock, while you’re scurrying around to try to rebrand and build other markets with mediocre drugs. Good luck. Your reality is the harsh one, not ours who have landed in better places. You created the problems and now you’re making a bigger mess trying to fix them. Typical. Customers are done with Genentech.

Remember, Novartis owns a decent percentage of Roche stock. That might complicate a purchase. Otherwise I agree with most of what you wrote.